Interventions for osteoporosis

Menopause

Volumn , Issue , 2007, Pages 351-375

  Keating, Fergus S J ^a   Stevenson, John C ^b  

^a Thames Ditton   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882910884     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369443-0/50035-1     Document Type: Chapter

References (266)

1. van Staa TP, Dennison EM, Leufkens HG, Cooper C Epidemiology of fractures in England and Wales. Bone 2001, 29:517-522.
2. Keene GS, Parker MJ, Pryor GA Mortality and morbidity after hip fractures. BMJ 1993, 307:1248-1250.
3. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002, 17:716-724.
4. Holt G, Khaw KT, Reid DM, et al. Prevalence of osteoporotic bone mineral density at the hip in Britain differs substantially from the US over 50 years of age: implications for clinical densit. Br J Radiol 2002, 75:736-742.
5. Cummings SR, Melton LJ Epidemiology and outcomes of osteopo-rotic fractures. Lancet 2002, 359:17 61-17 67.
6. Todd CJ, Freeman CJ, Camilleri-Ferrante C, et al. Differences in mortality after fracture of hip: the east Anglian audit. BMJ 1995, 310:904-908.
7. Melton LJI Epidemiology of fractures. Osteoporosis: etiology, diagnosis and management 1988, 133-154. Raven Press, New York. B.L. Riggs, L.J.I. Melton (Eds.).
8. Burge RT The cost of osteoporotic fractures in the UK Projections for 2000-2020. J Med Econ 2001, 4:51-62.
9. Consensus Development Conference Prophylaxis and treatment of osteoporosis. Am J Med 1991, 90:107-110.
10. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 1994, WHO, Geneva.
11. Hui SL, Slemenda CW, Johnston CC Age and bone mass as predic-tors of fractures in a prospective study. J Clin Invest 1988, 81:1804-1809.
12. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993, 8:1227-1233.
13. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N Perspective. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9:1137-1141.
14. Melton LJ III Epidemiology of fractures. Osteoporosis: Etiology, diagnosis and management 1995, 225-247. Lippincott-Raven, Philadelphia. 2. B.L. Riggs, L.J. I.I.I. Melton (Eds.).
15. Chrischilles EA, Butler CD, Davis CS, Wallace RB A model of lifetime osteoporosis impact. Arch Intern Med 1991, 151:2026-2032.
16. Singer BR, McLauchlan GJ, Robinson CM, Christie J Epidemiology of fractures in 15,000 adults: the influence of age and gender JBone. Joint SurgBr 1998, 80B:243-248.
17. Kanis JA, Johnell O, Oden A, De Laet C, Malstrom D Epidemiology of osteoporosis and fracture in men. Calcif Tissue Int 2004, 75:90-99.
18. Smith RW, Risek J Epidemiological studies of osteoporosis in women of Puerto Rico and southwestern Michigan. Clin Orthop 1962, 45:31-48.
19. Nordin BEC, Crilly RG, Smith DA Osteoporosis. Metabolic bone and stone disease 1984, 1-70. Churchill Livingstone, Edinburgh. B. Nordin (Ed.).
20. Alffram PS, Bauer G Epidemiology of fractures of the forearm. J Bone Joint Surg Am 1962, 44A:105-114.
21. Holbrook TL, Grazier K, Kelsey JL, Stauffer RN The frequency of occurrence, impact, and cost of selected musculoskeletal conditions in the United States 1984, American Academy of Orthopedic Surgeons, Chicago.
22. Ralston SH Osteoporosis (clinical review). Br Med J 1997, 315:469-472.
23. Slemenda CW, Christian JC, Williams CJ, Johnston CC Jr The changing relative importance of genetics and environment in adult women. Calcium regulation and bone metabolism 1990, 491-496. Elsevier Scientific, Amsterdam. D.V. Cohn, F.H. Glorieux, T.J. Martin (Eds.).
24. Chesnut CH Osteoporosis: a worldwide problem?. Osteoporosis 1990 1990, vol 1:33-35. Osteopress ApS, Copenhagen. S.C. Christian-, K. Overgaard (Eds.).
25. Melton LJ Epidemiology of fractures in North America. Osteoporosis 1990 1990, vol 1:36-41. Osteopress ApS, Copenhagen. C. Christiansen, K. Overgaard (Eds.).
26. Solomon L Bone density in aging Caucasian and African popula-tions. Lancet 1979, 3:1326-1329.
27. Lo CW, Jarjou LM, Poppitt S, et al. Delayed development of bone mass in West African adolescents. Osteoporosis 1990 1990, vol 1:73-77. Osteopress ApS, Copenhagen. C. Christiansen, K. Overgaard (Eds.).
28. Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF Determi-nants of bone density in normal women: risk factors for future osteo-porosis?. Br Med J 1989, 298:924-928.
29. Compston J The pathogenesis of osteoporosis. Osteoporosis illustrated 1997, 21. Current Medical Literature, London. N.K. Arden, T.T.D. Spec- (Eds.).
30. Mundy GR Bone remodelling and mechanisms of bone loss in osteoporosis. Osteoporosis diagnosis and management 1998, 17-35. Martin Dunitz, London. P.J. Meunier (Ed.).
31. Mbalaviele G, Chen H, Boyce BF, et al. The role of cadherin in the generation of multi-nucleated osteoclasts from mononuclear precur-sors in murine marrow JClin. Invest 1995, 95:2757-2765.
32. Mbalaviele G, Nishimura R, Feng J, et al. Molecular cloning of a novel cadherin in human osteoclasts (abstract). JBone Miner Res 1995, 10:10.
33. Horton MA, Davies J Perspectives: adhesion receptors in bone. J Bone Miner Res 1989, 4:803-807.
34. Parfitt AM Bone remodelling in the pathogenesis of osteoporosis. Med Times 1981, 109:80-92.
35. Mundy GR, Rodan SB, Majeska RJ, et al. Unidirectional migration of osteosarcoma cells with osteoblastic characteristics in response to products of bone resorption. Calcif Tissue Int 1982, 34:542-546.
36. Mundy GR, Poser JW Chemotactic activity of the gamma-carboxy-glutamic acid containing protein in bone. Calcif Tissue Int 1983, 35:164-168.
37. Pfeilschifter J, Wolf O, Naumann A, et al. Chemotactic response of osteoblast like cells to transforming growth factor. B. J Bone Miner Res 1990, 5:825-830.
38. Manolagas SC, Jilka RL Bone marrow, cytokines, and bone remodel-ling: emerging insights into the pathophysiology of osteoporosis. New Engl J Med 1995, 332:305-310.
39. Kurihara N, Civin C, Roodman GD Osteotropic factor responsive-ness of highly purified populations of early and late precursors for human multinucleated cells expressing the osteoclast phenot. Miner Res 1991, 6:257-261.
40. Ohsaki Y, Takahashi S, Scarcez T, et al. Evidence for an autocrine Jparacrine role for interleukin-6 in bone resorption by giant cells from giant cell tumours of bone. Endocrinology 1992, 131:2229-2234.
41. Albright F, Smith PH, Richardson AM Postmenopausal osteoporo-sis. J Am Med Assoc 1941, 116:2465-2474.
42. Albright F, Bloomberg E, Smith PH Postmenopausal osteoporosis. Trans Assoc Am Physicians 1940, 55:305.
43. Heaney RP A unified concept of osteoporosis. Am J Med 1965, 39:877.
44. Lindsay R Estrogen deficiency. Osteoporosis: etiology, diagnosis and management 1995, 133-160. Raven, New York. B.L. Riggs (Ed.).
45. Lindsay R Estrogen and osteoporosis. Osteoporosis 1998, 161-171. Chapman and Hall, London. J.C. Stevenson, R. Lindsay (Eds.).
46. Parfitt AM Bone forming cells in clinical conditions. The osteoblast and osteocyte. Bone 1990, vol 1:351-429. Telford JCRC, Boca Raton, FL. B.K. Hall (Ed.).
47. Heaney RP Menopausal effects on calcium homeostasis and skeletal metabolism. Menopause and aging 1973, 73-319. Government Printing Office, DHEW Publication (NIH), Bethesda, MD. K.J. Ryan, D.C. Gibson (Eds.).
48. Riggs BL, Jowsey J, Kelly PJ, Jones JD, Maher FT Effects of sex hor-mones on bone in primary osteoporosis. J Clin Invest 1969, 48:1065.
49. Recker RR, Saville PD, Heaney RP Effects of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 1977, 87:649.
50. Heaney RP, Recker RR, Saville PD Menopausal changes in bone remodelling. J Lab Clin Med 1978, 92:964-970.
51. Eriksen EF, Colvard DS, Berg NJ, et al. Evidence of estrogen recep-tors in normal human osteoblast-like cells. Science 1988, 241:84-86.
52. Komm BS, Terpening CM, Benz DJ, et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-84.
53. Rizzoli R, Bonjour J-P Hormones and bones. Lancet 1997, 349:s12020-s12023.
54. Girasole G, Jilka RL, Passeri G, et al. 17B estradiol inhibits interleu-kin-6 production by bone marrow-derived stromal cells and osteo-blasts in vitro: a potential mechanism for the antiresorptive. J Clin Invest 1992, 89:883-891.
55. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmeno-pausal estrogen therapy on bone density in elderly women. N Engl J Med 1993, 329:1141-1146.
56. Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987, 317:1169-1174.
57. Lafferty FW, Fiske ME Postmenopausal estrogen replacement: a long-term cohort study. Am J Med 1994, 97:66-77.
58. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980, 303:1195-1198.
59. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995, 122:9-16.
60. Paganini-Hill A, Ross RK, Gerkins VR, et al. Menopausal estrogen therapy and hip fractures. Ann Intern Med 1982, 95:28-31.
61. Ettinger B, Genant HK, Cann CE Long-term estrogen therapy prevents bone loss and fractures. Ann Intern Med 1985, 102:319-324.
62. Hutchinson TA, Polansky SM, Feinstein AR Postmenopausal oes-trogens protect against fractures of hip and distal radius. Lancet 1979, ii:705-709.
63. Hillard TC, Whitcroft SJ, Marsh MS, et al. Long-term effects of transdermal and oral hormone replacement therapy on postmeno-pausal bone loss. Osteoporos Int 1994, 4:341-348.
64. Lindsay RTohme JF Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990, 76:290-295.
65. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementa-tion, and hormone replacement therapy. N Engl J Med 1991, 325:1189-1195.
66. Lindsay R, Hart DM, Aitken JM, et al. Long-term prevention of post-menopausal osteoporosis by oestrogen: evidence for increased bone mass after onset of oestrogen treatment. Lancet 1976, i:1038-1041.
67. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy. I. A 10-year prospective study in relationship to osteoporosis. Obstet Gynecol 1979, 53:277-281.
68. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of post-menopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1-9.
69. Al-Azzawi F, Hart DM, Lindsay R Long-term effects of oestrogen replacement therapy on bone mass as measured by dual photon ab-sorptiometry. Br Med J 1987, 294:1261-1262.
70. Lees B, Stevenson JC The prevention of osteoporosis using sequen-tial low-dose hormone replacement therapy with estradiol-17β and dydrogesterone. Osteoporos Int 2001, 12:251-258.
71. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH Effect of lower doses of conjugated equine estrogens with and without medroxypro-gesterone acetate on bone in early postmenopausal women. J Am Med Assoc 2002, 287:2668-2676.
72. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004, 104:443-451.
73. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. J Am Med Assoc 2003, 290:1729-1738.
74. Women's Health Initiative Steering Committee Effects of conju-gated equine estrogen in postmenopausal women with hysterectomy. J Am Med Assoc 2004, 291:1701-1712.
75. Lamy O, Kreig MA, Burckhardt B, Wasserfallen JB An economic analysis of hormone replacement therapy for the prevention of frac-ture in young postmenopausal women Expert. Opin Pharmacother 2003, 4:1479-1488.
76. Holland EFN, Leather AT, Studd JWW The effect of a new sequen-tial oestradiol valerate and levonorgestrel preparation on the bone density of postmenopausal women. Br J Obstet Gynaecol 1993, 100:966-967.
77. Lees B, Pugh M, Siddle N, et al. Changes in bone density in women starting hormone replacement therapy compared to those in women already established on hormone replacement therapy. Osteoporos Int 1995, 5:344-348.
78. Riis BJ, Thomsen K, Strom V, et al. The effects of percutaneous es-tradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987, 156:61-65.
79. Stevenson JC, Cust MP, Ganger KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990, 335:265-269.
80. Studd JWW, Holland EFN, Leather AT, et al. The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994, 101:787-791.
81. Ryde SJS, Bowen-Simpkins K, Bowen-Simpkins P, et al. The effect of oestradiol implants on regional and total body mass: a three-year longitudinal study. Clin Endocrinol 1994, 40:33-38.
82. Naessén T, Persson I, Thor L, et al. Maintained bone density at ad-vanced ages after long term treatment with low dose oestradiol im-plants. Br J Obstet Gynaecol 1993, 100:454-459.
83. Persson I, Actam HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in adjunction with progesto-gens: results of a prospective study. Br Med J 1989, 28:147-151.
84. Christiansen C, Riis BJ 17-β oestradiol and continuous norethister-one: an unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990, 71:836-841.
85. Nielsen SP, Bärenholdt O, Hermansen F, et al. Magnitude and pat-tern of skeletal response to long term continuous and cyclical sequen-tial oestrogen/progestin treatment. Br J Obstet Gynaecol 1994, 101:319-324.
86. Lindsay R, Hart DM, Purdie P, et al. Comparative effects of oestro-gen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med 1978, 54:193-195.
87. Bagger YZ, Tankó LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004, 34:728-735.
88. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002, 288:321-333.
89. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362:419-427.
90. Stevenson JC on behalf of the International Consensus Group on HRTand Regulatory Issues HRT, osteoporosis and regulatory authorities. Quis custodiet ipsos custodes?. Human Reprod 2006, 21:1668-1671.
91. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
92. 99mTc diphosphonate mechanism on bone. Bone uptake scanning in clinical practice 1987, 7-17. Springer-Verlag, London. I. Fogelman (Ed.).
93. Francis MD The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 1969, 3:151-162.
94. Reynolds JJ, Minkin C, Morgan DB, Spycher D, Fleisch H The ef-fect of two diphosphonates on the resorption of mouse calvaria in vitro. Calcif Tissue Res 1972, 10:302-313.
95. Fleisch H Bisphosphonates: pharmacology and use in treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42:919-944.
96. Actami S, Zamberlan N, Mian M, et al. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism. Bone Miner 1994, 5:75-82.
97. Nixon GA, Buehler EV, Newmann EA Preliminary safety assessment of disodium etidronate as an additive to experimental oral hygiene products. Toxicol Appl Pharmacol 1972, 22:661-671.
98. Nolen GA, Buehler EV The efffect of disodium etidronate on the reproductive functions and embryogeny of albino rats and New Zealand rabbits. Toxicol Appl Pharmacol 1971, 18:548-561.
99. Gralpel P, Bentley P, Fritz H, et al. Reproduction toxicity studies with pamidronate. Arzneimittel Forschung 1992, 42:654-667.
100. Minsken DH, Manson JM, Chennekatu PP Effects of the biphos-phonate, alendronate, on parturition in rats. Toxicol Appl Pharmacol 1993, 121:217-233.
101. 3H-etidronate in rat and mouse bones. Bone 1996, 19:281-290.
102. 2MBP-coated bone. Bone Miner 1989, 6:33-43.
103. Hughes DE, Wright KR, Vy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo JBone. Miner Res 1995, 10:1478-1487.
104. Sat M, Grasse W, Endo M, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Invest 1991, 88:2095-2105.
105. Hughes DE, MacDonald BR, Rissell RGG, Gonan M Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cul-tures of human bone marrow. J Clin Invest 1989, 83:1930-1935.
106. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarised osteoclasts having ruffled borders. Bone 1995, 17:137-144.
107. Skovey IA, Ly HD, Kelly J, et al. How does alendronate inhibit protein-tyrosine phosphotases?. J Biol Chem 1997, 272:2472-2480.
108. Sahni M, Guenther H, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993, 91:2004-2011.
109. Vitte C, Fleisch H, Guenther H Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinol-ogy 1996, 137:2324-2333.
110. Pouillies JM, Tremollieres F, Roux C, et al. Cyclical etiodronate for the prevention of early postmenopausal bone loss. Osteopor Int 1996, 6:242-246.
111. Pouillies JM, Tremollieres F, Roux C, et al. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are undergo-ing hormonal replacement therapy. Osteoporos Int 1997, 213-218.
112. Herd RJM, Balena R, Blake GM, Ryan PJ, Fogelman I The preven-tion of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 1997, 103:92-99.
113. Meunier PJ, Confravreux E, Tupinon I, et al. Prevention of early postmenopausal bone loss with cyclincal etidronate therapy (a double-blind, placebo-controlled study and one-year follow-up). J Clin Endo-crinol Metab 1997, 82:2784-2791.
114. Livermay VA, Weiss SR, Broil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N Engl J Med 1995, 333:1437-1443.
115. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of ef-fect of alendronate on risk of fracture in women with existing verte-bral fractures. Lancet 1996, 348:1535-1541.
116. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate. A meta-analysis. JAMA 1997, 277:1154-1164.
117. Hosking D, Chilvers C, Christiansen C, et al. Prevention of bone loss with Alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998, 338:485-492.
118. McClung MR, Geusens P, Miller PD, et al. Hip intervention pro-gram study group: effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001, 344:333-340.
119. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedrona. Osteoporos Int 2000, 11:83-91.
120. Woo S-B, Hellstein JW, Kalmar JR Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Int Med 2006, 144:753-761.
121. Chestnut CH, Skag A, Christiansen C, et al. Effects of oral iban-dronate administered daily or intermittently on fracture risk in post-menopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
122. Kanis JA, Passmore R Calcium supplement of the diet: 1. Br Med J 1989, 298:137-140.
123. Nordin CBE, Heaney RP Calcium supplementation in the diet: justified by present evidence. Br Med J 1990, 300:1056-1060.
124. Cadogan J, Eastell R, Jones N, Barker ME Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled inter-vention trial. Br Med J 1997, 315:1555-1560.
125. Nordin BEC, Peacock M Calcium and bone metabolism. Progress in clinical medicine 1983, 287-315. Churchill Livingstone, Edinburgh. A.R. Horler, J.B. Foster (Eds.).
126. Hagenfeldt Y, Eriksson HA The oestrogen receptor in the rat kidney: ontogeny, properties and effects of gonadoectomy on its concentra-tion. J Steroid Biochem 1988, 31:49-56.
127. Lau E, Donnan S, Barker DJP, Cooper S Physical activity and cal-cium intake in fracture of the proximal femur in Hong Kong. Br Med J 1988, 297:1441-1443.
128. Cooper S, Barker DJP, Wickham C Physical activity, muscle strength and calcium intake in fracture of the proximal femur in Britain. Br Med J 1998, 297:1443-1446.
129. Kanis JA, Johnell O, Gullberg B, et al. Evidence of efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992, 305:1124-1128.
130. Dawson-Hughes B, Dallai GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmeno-pausal women. N Engl J Med 1990, 323:878-883.
131. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. N Engl J Med 1991, 325:1189-1195.
132. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementa-tion on bone loss in postmenopausal women TV. Engl J Med 1993, 328:460-464.
133. Riis B, Thomsen K, Christiansen C Does calcium supplement pre-vent postmenopausal bone loss?. N Engl J Med 1987, 316:173-177.
134. Nicar MJ, Pak CYC Calcium bioavailability from calcium carbonate and calcium citrate. J Clin Endocrinol Metab 1985, 61:391-393.
135. Harvey JA, Zobitz MM, Pak CYC Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. J Bone Mineral Res 1988, 3:253-258.
136. Reginster JY, Denis D, Bartsch V Acute biochemical variations in-duced by four different calcium salts in healthy male volunteers. Os-teopor Int 1993, 3:271-275.
137. Hunt JN, Johnson C Relationship between gastric secretion of acid and urinary excretion of calcium after oral supplements of calcium. Digest Dis Scien 1983, 28:417-421.
138. Recker R Calcium absorption and achlorhydria TV. Engl J Med 1985, 313:70-73.
139. Reichnel H, Koeffler HP, Norman AW The role of the vitamin D endocrine system in health and diseases. N Engl J Med 1989, 320:981.
140. 3 receptors. Structure and function in transcription. Annu Rev Nutr 1991, 11:189.
141. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptors alleles. Nature 1994, 367:284-287.
142. Howard G, Nguyen T, Morrison N, et al. Genetic influence on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metabol 1995, 80:2800-2805.
143. Jorgensen HL, Scholler J, Sand JC, et al. Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: cross-sectional and longitudinal popula. Br Med J 1996, 313:586-590.
144. Looney J, Yoon HK, Fischer M, et al. Lack of high prevalence of Bb vitamin D receptor genotype in severely osteoporotic women J Clin Endocrinol. Metabol 1995, 80:2158-2162.
145. Holick MF, Shao QM Liu WW, Chen TC The vitamin D content of fortified milk and infant formula TV. Engl J Med 1992, 326:1178-1181.
146. Lips P, Grafmans WC, Ooms ME, Bezemer PD, Bouter LM Vitamin D supplementation and fracture incidence in elderly persons. A randomised, placebo-controlled clinical trial. Ann Intern Med 1996, 124:400-406.
147. Smith H, Anderson F, Raphael H, Crozier S, Cooper C Effect of annual intramuscular vitamin D supplementation on fracture risk: population-based, randomised, double-blind, placebo-controlled trial. Osteoporos Int 2004, 15:S8.
148. 3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium or Vi. Lan-cet 2005, 365:1621-1628.
149. Trivedi DP, Doll R, Khaw KT Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised doubl. BMJ 2003, 326:469-572.
150. Dawson-Hughes B, Harris SS, Krall EA, Dalla GE Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997, 337:670-676.
151. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D and calcium to prevent hip fractures in elderly women TV. Engl J Med 1992, 327:1637-1642.
152. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the De. Osteoporos Int 2002, 13:257-264.
153. Larsen ER, Mosekilde L, Foldsprang A Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly communitydwelling residents: a pragmatic population-based 3-year intervention. J Bone Miner Res 2004, 19:370-378.
154. 3) for prevention of fractures in primary care. BMJ 2005, 330:1003-1006.
155. Jackson RD, LaCroix AZ, Gass M, et al. Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
156. Sogaard CH, Mosekilde L, Thomsen JS, Richard A, McOsker JE A comparison of the effects of two anabolic agents (fluoride and PTH) on ash mineral density and bone strength assessed in an osteopenic rat model. Bone 1997, 20:439-449.
157. Ejersted C, Andreassen TT, Nilsson MHL, et al. Human parathyroid hormone (1-34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol 1994, 130:210-217.
158. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 1990, I:1340-1344.
159. Finkelstein JS, Klibanski A, Schaefer EH, et al. Parathyroid hormone for the prevention of bone loss induced by oestrogen deficiency. N Engl J Med 1994, 331:1618-1623.
160. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteop. Lancet 1997, 350:550-555.
161. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmeno-pausal women with osteoporosis TV. Engl J Med 2001, 344:1434-1441.
162. Tashjian AH Jr, Chabner BA Commentary on clinical safety of re-combinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002, 17:1151-1161.
163. Marcus R, Wang O, Satterwhite J, Mitlak B The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women w. J Bone Miner Res 2003, 18:18-23.
164. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) teriparatide J improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
165. Rich C, Enskinck J Effect of sodium fluoride on calcium metabolism of human beings. Nature 1961, 191:184-185.
166. Kleerecoper M The role of fluoride in the prevention of osteoporosis. Endocrinol Metab Clin NAm 1998, 27:441-452.
167. Riggs BL, Hogson SF, O'Fallam MW, et al. Effect of fluoride treat-ment on the fracture rate in postmenopausal women with osteoporo-sis. N Engl J Med 1990, 352:802-809.
168. Pak CYC, Sakhaee K, Actams-Huet B, et al. Treatment of postmeno-pausal osteoporosis with slow-release sodium fluoride. Ann Intern 1995, 123 Med:401-408.
169. Heaney RP Fluoride and osteoporosis. Ann Intern Med 1994, 120:689-690.
170. Kleerekoper M Osteoporosis and the primary care physician: time to bone-up. Ann Intern Med 1995, 123:466-467.
171. Eastell R, Boyle IT, Compston J, et al. Management of male osteopo-rosis: report of the UK Consensus Group. QJM 1998, 91:71-92.
172. Chambers TJ, Moore A The sensitivity of isolated osteoclasts to morphological transformation by calcitonin/C/m. Endocrinol' Metab ol 1983, 57:819-825.
173. Nicholson GC, Horton MA, Sexton PM, et al. Calcitonin receptors of human osteoclastoma. Honn Metab Res 1987, 19:585-589.
174. Azria M, Copp DH, Zanelli JM 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 1995, 57:405-408.
175. Reginster JY, Gaspar S, Deroisy R, et al. Prevention of osteoporosis with nasal salmon calcitonin-effect of anti-salmon calcitonin antibody formation. OsteoporInt 1998, 3:261-264.
176. Stevenson JC, Hillyard CJ, Maclntyre I, Cooper H, Whitehead ML A physiological role for calcitonin: protection of the maternal skeleton. Lancet 1979, ii:769-770.
177. Hillyard CJ, Stevenson JC, Maclntyre I Relative deficiency of plasma-calcitonin in normal women. Lancet 1978, i:961-962.
178. Taggart HM, Chesnut CH, Ivey JL, et al. Deficient calcitonin re-sponse to calcium stimulation in post-menopausal osteoporosis. Lan-cet 1982, 1:475-478.
179. Stevenson JC, Allen PR, Abeyasekera G, Hill PA Osteoporosis with hip fracture: changes in calcium regulating hormones. Eur J Clin In-vest 1986, 16:357-360.
180. Tiegs RD, Body JJ, Wahner HW, et al. Calcitonin secretion in post-menopausal osteoporosis. N Engl J Med 1985, 312:1000-1097.
181. Maclntyre I, Stevenson J, Whitehead M, et al. Calcitonin for preven-tion of postmenopausal bone loss. Lancet 1988, 1:900-902.
182. Overgaard K, Riis BJ, Christiansen C, et al. Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 1989, 299:477-479.
183. Ellerington MC, Hillard TC, Whitcroft SIJ, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteo-porosis. Calcif Tissue Int 1996, 59:6-11.
184. Overgaard K, Hansen MA, Jensen SB Effects of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 1992, 305:556-561.
185. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F Salmon calcitonin reduces vertebral fracture rates in postmenopausal crush fracture syndrome. Bone Miner 1992, 16:131-138.
186. Cardona JM, Pastor E Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporos Int 1997, 7:165-174.
187. Arnala I, Saastamonen J, Alhava EM Salmon calcitonin in the pre-vention of bone loss in the perimenopause. Bone 1996, 4:629-632.
188. Chestnut CH, Silverman S, Adriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with estab-lished osteoporosis: the Prevent Recurrences of Osteoporotic Frac-tures. Am J Med 2000, 109:267-276.
189. Benedek-Jaszman LJ Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987, 1:S25-S33.
190. Lippuner K, Haenggi W, Birkhaeuser MH, et al. Prevention of post-menopausal bone loss using tibolone or conventional per oral or transdermal hormone replacement therapy with 17 beta estradiol and dydroges. J Bone Mine Res 1987, 12:806-812.
191. Lindsay R, Hart DM Prospective double-blind trial of a synthetic steroid (Org OD14) for prevention of postmenopausal osteoporosis. Br Med J 1980, 1:1207-1209.
192. Lyritis GP, Karpathios S, Basdecis K, et al. Prevention of post-oopho-rectomy bone loss with Tibolone. Maturitas 1995, 22:247-253.
193. Geusens P, Dequeker J, Gielen J, Schot LPC Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991, 13:155-162.
194. Kenemans P, Speroff L, Birkhauser M, et al. Tibolone: clinical
195. Cummings SR LIFT study is discontinued. BMJ 2006, 332:667.
196. Genazzani AR, Benedek-Jaszman LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas 1991, 13:243-251.
197. Von Dadelszen P, Gillmer MDG, Gray MD, et al. Endometrial hy-perplasia and adenocarcinoma during Tibolone (Livial) therapy. Br J Obstet Gynaecol 1994, 101:158-161.
198. Milner MH, Sinnott MM, Cooke TM, et al. A two-year study of lipid and lipoprotein changes in postmenopausal women with tibo-lone and estrogen-progestin. Obstet Gynecol 1996, 87:593-599.
199. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC Effects of tibolone on serum concentrations of lipoprotein (a) in postmeno-pausal women. Acta Endocrinol 1993, 128:259-262.
200. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease J Clin Endocrinol. Metab 1997, 82:1752-1756.
201. Zumoff B, Strain GW, Miller LK, Rosner W Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995, 80:1429-1430.
202. Meldrum DR, Davidson BJTataryn IV, Judd HL Changes in circu-lating steroids with aging in postmenopausal women. Obstet Gynaecol 1981, 57:624-628.
203. Judd HL, Lucas WE, Yen SSC Effect of oophorectomy on circulat-ing testosterone and androstenedione levels in patients with endome-trial cancer. Am J Obstet Gynecol 1974, 118:793-798.
204. Colvard CS, Ericsen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblastic-like cells. Proc Natl Acad Sci 1989, 86:854-857.
205. Kasperk CH, Wergedal JE, Farley JR, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989, 124:1576-1578.
206. Thorn MH, Studd JWW Hormonal profile in postmenopausal women after therapy with subcutaneous implant. Br J Obstet Gynaecol 1981, 88:426-433.
207. Devogelaer JP, Crabbe J, De Deuxchaisnes CN Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J 1987, 294:798-800.
208. Watts NB, Notelovitz M, Timmons MC, et al. Comparison of oral oestrogen and oestrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical meno-pause. Obstet Gynaecol 1995, 85:529-537.
209. Hickok LR, Toomey C, Speroff L A comparison of oesterified estro-gens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynaecl 1993, 82:919-924.
210. Sawas M, Studd JWW, Normah S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in postmenopausal women who have previously received long-term oral. Br J Obstet Gynaecol 1992, 99:757-760.
211. Davis SR, Burger HG Androgens and the postmenopausal women. J Clin Endocrinol Metab 1996, 81:2759-2763.
212. Need GA, Horowitz M, Bridges A, et al. Effects of nandrolone dec-anoate and anti-resorptive therapy on vertebral density in osteopo-rotic women. Arch Intern Med 1989, 149:57-60.
213. 3 or intermittent calcium infusion therapy on bone mineral content, bone remodelling an. Bone Miner 1986, 1:347-357.
214. Passeri M, Pedrazzoni M, Pioli G, et al. Effects of nandrolone dec-anoate on bone mass in established osteoporosis. Maturitas 1993, 17:211-219.
215. Sherwin BB, Gelfand MM Differential symptom response to paren-teral oestrogen and/or androgen administration in the surgical meno-pause. Am J Obstet Gynaecol 1985, 151:153-160.
216. Burger H, Hailes J, Nelson J, Menelaus M Effects of combined im-plants on oestradiol and testosterone and libido in postmenopausal women. Br Med J 1987, 294:936-937.
217. Myers LS, Dixen J, Morrissette D, et al. Effects of estrogen, andro-gen, and progestin on sexual psychophysiology and behavior in post-menopausal women. J Clin Endocrin Metabol 2000, 79:1124-1131.
218. Stevenson JC, Banks LM, Spinks TJ, et al. Regional and total skeletal measurements in the early postmenopause. J Clin Invest 1987, 80:258-262.
219. Recker RR, Davies MK, Hinders SM, et al. Bone gain in young adult women. JAMA 1992, 268:2403-2408.
220. Rubin CT, Lanyon LE Osteoregulatory nature of mechanical stimuli: function as a determinant for adaptive remodelling in bone J. Orthop Res 1987, 5:300-310.
221. Taaffe DR, Snow-Carter C, Connolly DA, et al. Differential effect of swimming versus weight bearing activity on bone mineral status of amenorrhoeac athletes. J Bone Miner Res 1995, 10:586-589.
222. Taaffe DR, Robinson TL, Snow CM, Markus R High-impact exer-cise promotes bone gain in well-trained female athletes. J Bone Miner Res 1997, 12:255-260.
223. Wolman RL Osteoporosis and exercise. Br Med J 1994, 309:400-403.
224. Etherington J, Harris PA, Nandra D, et al. The effect of weight-bearing exercise on bone mineral density: a study of female ex-elite athletes and the general population. J Bone Miner Res 1996, 11:1333-1338.
225. Skerry TM Mechanical loading and bone: what sort of exercise is beneficial to the skeleton. Bone 1997, 2:179-181.
226. Szoller SM, Martin EM, Parthermore JG, Sartoris DJ, Defros LJ Demineralisation in tetraplegic and paraplegic man over time. Spinal Cord 1997, 35:223-228.
227. Goemaere S, Van Laere M, De Neve P, Kaufman JM Bone mineral status in paraplegic patients who do or do not perform standing. Osteopor lnt 1994, 4:138-143.
228. Rambaut PC, Goode AW Skeletal changes during space flight. Lan-cet 1985, ii:1050-1053.
229. Hainonen A, Kannus P, Oja P, et al. Randomised controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures. Lancet 1996, 348:1343-1347.
230. Nelson ME, Fiatarone MA, Morganti CM, et al. Effect of high-in-tensity strength training on multiple risk factors for osteoporotic fractures. JAMA 1994, 272:1909-1914.
231. Paganini-Hill A, Chao A, Ross RK, Henderson BE Exercise and other factors in the prevention of hip fracture: the leisure world study. Epidemiology 1991, 2:16-25.
232. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial interven-tion to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994, 331:8221-8227.
233. Province MA, Hadley EC, Hornbrook MC, et al. The effect of exer-cise on falls in elderly patients. JAMA 1995, 273:1341-1347.
234. Sato M, Glasebrook AL, Bryant HU Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metabol 1994, 12:519-520.
235. Yang NN, Venugopalan M, Hardikar S, Glesebrook A Identification of an oestrogen response element activated by metabolites of 17-beta estradiol and raloxifene. Science 1996, 273:1222-1225.
236. Cole MP, Jones CTA, Todd IDH A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46 474. Br J Cancer 1971, 25:270-275.
237. Ward HWC Antioestrogen therapy for breast cancer: a trial of tamoxifen at two-dose levels. Br Med J 1973, 1:13-14.
238. Wright CDP, Garrahan NJ, Stanton M, et al. Effect of long-term tamoxifen therapy on cancellous bone remodelling and structure in women with breast cancer. J Bone Miner Res 1994, 9:153-159.
239. Grey AB, Stapleton JP, Evans MC, et al. The effect of the antioestro-gen tamoxifen on bone mineral density in normal late postmeno-pausal women. Am J Med 1995, 99:636-641.
240. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326:852-856.
241. Powels TJ, Hickish T, Kanis JA, Tidy A, Ashby S Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiom-etry in healthy premenopausal and postmenopausal women JClin. Oncol 1996, 14:78-84.
242. Love PR, Barden HS, Mazess RB, Epstein S, Chappell RJ Effects of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 1994, 154:2585-2588.
243. Fornander T, Rutqvist LE., Sjoberg HE, et al. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 1990, 8:1019-1024.
244. Andersen HT, Kristensen B, Ejlertsen B, Andersen KW, Lauritsen JB Fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast 1995, 4:245-246.
245. Clements JA, Bennett DR, Black LJ, Jones CD Effects of a new antioestrogen, keoxifene (LY 1567758) on carcinogen-induced mam-mary tumours and on LH and prolactin levels. Life Sci 1983, 32:2869-2875.
246. Wakeling AE, Valcaccia B, Newboult E, Green LR Non-steroidal antioestrogens: receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells JSteroid. Bio Chem 1984, 20:111-120.
247. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G Phase II evaluation of LY 156758 in metastatic breast cancer. Oncology 1988, 45:344-345.
248. Sato M, Rippy MK, Bryant HU Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 1996, 10:1.
249. Heany RP, Draper MW Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab 1997, 82:3425-3429.
250. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:1641-1647.
251. Ettinger B, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxi-fene: results from a 3-year randomized clinical trial. JAMA 1999, 282:637-645.
252. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006, 355:125-137.
253. Murkies AL, Lombard C, Strauss BJG, et al. Dietary flour supple-mentation decreases postmenopausal hot flushes: effect of soy and wheat. Maturitas 1995, 21:189-195.
254. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998, 91:6-11.
255. Wilcox G, Wahlqvist ML, Burger HG, Medley G Oestrogenic ef-fects of plant foods in postmenopausal women. Br Med J 1990, 301:905-906.
256. Reginster JY Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993, 23:223-232.
257. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Genazzani AR Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997, 28:75-81.
258. Agnusdei D, Crepaldi G, Isaia G, et al. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss. Calcif Tissue Int 1997, 61:142-147.
259. Agnusdei D, Bufalino L Efficacy of ipriflavone in established osteo-porosis and long term safety. Calcif Tissue Int 1997, 61:S23-S27.
260. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmeno-pausal osteoporosis. N Engl J Med 2004, 350:459-468.
261. Marshall JH, Lloyd EL, Rundo J, et al. Alkaline earth metabolism in adult man. A report prepared by a task group of Committee 2 of the International Commission on Radiological Protection (ICRP publ. Health Phys 1973, 24:129-221.
262. Meunier PJ, Slosman D, Delmas P, et al. Strontium ranelate: dose dependent effects in established postmenopausal vertebral osteoporo-sis: a 2-year randomized placebo-controlled trial J Clin Endocrin. Metab 2002, 87:2060-2066.
263. Reginster JY, Spector T, Badurski J, et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The Strontium Ranelate Phase III Program. Osteo-Poros Int 2002, 13:S30.
264. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmeno-pausal osteoporosis. N Engl J Med 2004, 350:459-468.
265. Reginster JY, Seeman E, De Vernejoul MC, et al. Stontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005, 90:2816-2822.
266. Fogelman I, Blake GM Strontium ranelate for the treatment of os-teoporosis. BMJ 2005, 330:1400-1401.